Nexavar, der blev givet samtidigt med irinotecan, hvis aktive metabolit SN- 38 metaboliseres yderligere af UGT1A1- systemet, gav en 67 - 120% stigning i AUC for SN- 38 og en 26 - 42% stigning i AUC for irinotecan.
When administered with irinotecan, whose active metabolite SN-38 is further metabolised by the UGT1A1 pathway, there was a 67 - 120% increase in the AUC of SN-38 and a 26 - 42% increase in the AUC of irinotecan.